The renal-coloboma syndrome (RCS, MIM 120330) is an autosomal dominant disorder caused by PAX2 gene mutations. We screened the entire coding sequence of the PAX2 gene for mutations in nine patients with RCS. We found five heterozygous PAX2 gene mutations: a dinucleotide insertion (2G) at position 619 in one sporadic RCS case, a single nucleotide insertion (619 + G) in three unrelated cases, and a single nucleotide deletion in a familial case. In this familial case, three affected sibs showed a striking ocular phenotypic variability. Each of the sibs carried a 619insG mutation, whilst unaffected parents did not, suggesting the presence of germline mosaicism. Interestingly, the 619insG mutation has been previously reported in several patients and is also responsible for the Pax2 1Neu mouse mutant, an animal model of human RCS. This study confirms the critical role of the PAX2 gene in human renal and ocular development. In addition, it emphasises the high variability of ocular defects associated with PAX2 mutations ranging from subtle optic disc anomalies to microphthalmia. Finally, the presence of PAX2 germline mosaicism highlights the difficulties associated with genetic counselling for PAX2 mutations. European Journal of Human Genetics (2000) 8, 820-826.
Introduction
In humans, PAX gene mutations are responsible for Waardenburg syndrome type I and III (PAX3 1 ), aniridia and Peter's anomaly (PAX6 2-4 ), thyroïd dysgenesis (PAX8 5 ), oligodontia (PAX9 6 ) and renal-coloboma syndrome (RCS, PAX2 7 ). RCS is a rare autosomal dominant disorder (MIM 120330) associating optic nerve coloboma and retinal epithelium thinning, renal hypoplasia, vesico-ureteral reflux and mild sensorineural hearing loss. In 1995, Sanyanusin et al first reported a PAX2 mutation in patients with renal and ocular defects. 7 Since then, eight different PAX2 mutations and a chromosome 10/13 de novo translocation have been identified in 13 unrelated patients. [7] [8] [9] [10] [11] [12] [13] [14] It has been shown that PAX2 gene mutations are associated with both inter and intrafamilial phenotypic variability; all patients share renal and ocular abnormalities, while some present with hearing loss, mental retardation or seizures. 9 Several Pax2 mutant mice are known: Pax2 1Neu resulting from a Pax2 frameshift mutation, 15 Krd carrying a large chromosomal deletion encompassing the Pax2 gene (kidney and retinal defect, 16 ), and the Pax2 knock-out mouse. 17, 18 All the mouse mutants have kidney and optic nerve or retinal defects.
Here we report the identification of PAX2 mutations in five out of nine unrelated RCS patients, and two are previously undescribed mutations. In one familial case, unaffected parents did not carry the mutation suggesting the presence of germline mosaicism involving the paternal allele. The finding that the G619 insertion has occurred three times independently in our series as well as in seven other cases of RCS, and that we have also observed a novel 619insGG suggests the existence of a poly G mutational hot-spot of the PAX2 gene.
Materials and methods

Patients and families
A total of nine patients with renal abnormalities and coloboma were studied for PAX2 mutations. Table 1 summarises the clinical features of the patients.
Detection of PAX2 mutations and large deletion
Genomic DNA was extracted from peripheral blood samples using standard protocols. PCR was carried out using intronic primers for the 12 exons of the PAX2 gene. 19 
Results
We screened the entire coding sequence of the PAX2 gene for mutations in RCS patients and report 3 different PAX2 mutations ( Figure 1 ) in five unrelated RCS patients with variable ocular findings. Table 1 summarises the phenotype of all the patients and the mutations identified.
A previously not described PAX2 gene mutation (a dinucleotide insertion GG at position 619) was identified in an isolated RCS case showing bilateral optic nerve coloboma and bilateral renal hypoplasia (patient NI). This frameshift mutation predicts a premature termination of the protein 3 codons downstream from the mutation ( Figure 1A and 1C) . The mother did not carry the mutation but the healthy father was not available for DNA study.
A single nucleotide insertion (G) at position 619 was found in an isolated case with bilateral renal hypoplasia associated with bilateral microphthalmia and retinal degeneration (patient RA, Figure 3A ). Irides were normal. Parents were not available for DNA study. As with the previous mutation, the 619insG frameshift mutation predicts a premature termination of the protein 27 codons downstream from the insertion. The same mutation was identified in a sporadic case with bilateral renal hypoplasia associated with bilateral retinal coloboma (patient PE, Figure 1A and 1B). Parents were studied and did not carry the mutation suggesting the presence of a de novo mutation.
A family with three affected sibs were studied (patients AR, Figure 2 ). Patient II1 had bilateral renal hypoplasia and a 'morning-glory syndrome' (equivalent to an optic coloboma), whilst II2 and II3 presented with isolated unilateral cystic renal hypoplasia with no ocular manifestation. Careful ophthalmological examination showed an optic disc anomaly in both of them: bilateral papillary dysplasia in II2 ( Figure 3B ) and bilateral optic nerve coloboma in II3 ( Figures  3C and 3D) . A 619insG was identified in all three children of this family. Both unaffected parents did not carry the mutation, however, suggesting a germline mosaicism (Figure 2) . The study of a PAX2 intragenic DNA microsatellite marker showed that the mutation was of paternal origin. False paternity was excluded by the study of polymorphic markers. Figure 1D ). This mutation was identified in a family where a child presented bilateral optic nerve coloboma, severe myopia and unilateral renal agenesis, whilst his father had bilateral optic nerve coloboma with association to a chorioretinal coloboma ( Figures 3E and 3F ). Renal explorations in the father showed renal insufficiency and slight reduction in kidney size. The 832delG frameshift mutation predicts a premature termination of the protein 61 codons downstream from the deletion and has not been reported previously.
None of these mutations was observed in a panel of 100 control chromosomes.
Finally, the PAX2 intragenic microsatellite marker study showed the presence of two alleles in all patients except one. In this patient, a karyotype and FISH analysis indicated that both copies of the PAX2 gene were present. Thus, in all patients tested, no evidence of a large PAX2 gene deletion could be found.
Discussion
The PAX genes comprise a family of developmental genes encoding nuclear transcription factors. 20 They are characterised by a conserved amino acid motif with DNA binding activity, the paired domain. Nine members of this family have been isolated in human and mouse, and classified into four groups sharing structural motifs (ie octapeptide and homeodomain) and sequence similarities. Disruption of at least five PAX genes has been shown to result in developmental abnormalities in humans. [1] [2] [3] [4] [5] [6] [7] So far, eight different PAX2 mutations have been reported in 13 patients with RCS. [7] [8] [9] [10] [11] [12] [13] In all previously reported cases, patients presented with RCS or renal hypoplasia with mild ocular manifestations described as optic disc dysplasia or papillo-renal syndrome. Here, we report on five additional cases of PAX2 mutations in patients with RCS. One novel mutation resulted from a 2 guanine nucleotides insertion within a stretch of 7 guanines in exon 2 of the PAX2 gene. In three other patients, a single G insertion at the same position has been identified. This latter mutation has already been reported in several patients. Finally, we identified a novel guanine deletion at position 832 in a familial RCS. We failed, however, to find either a PAX2 mutation or a large deletion in 4/9 RCS patients examined. Although the promotor region as well as the non-coding sequences of the PAX2 gene have not yet been studied, these results suggest that the RCS might be genetically heterogeneous. Interestingly, in one familial case, a paternal germline mosaicism was observed. Furthermore, in this family, the clinical spectrum was quite variable with ocular anomalies being detected only after careful ophthalmological examination in two out of three sibs. This observation confirms findings of previous studies showing that all patients with PAX2 mutations present with an abnormal eye fundus, even a very subtle one.
Along with the mutations reported here and unpublished data (Salomon et al, 2000 personal communication), 11 different PAX2 mutations have been hitherto identified in 20 unrelated patients. They are summarised in Figure 4 . In addition, a 10/13 translocation within either intron 3 or 4 of the PAX2 gene has been reported. 14 With the exception of two mutations in exons 5 and 7, all PAX2 gene mutations reported so far are located in the paired domain (exons 2 and 3). Interestingly, 17/20 mutations are frameshift mutations predicting a truncated and non-functional PAX2 protein lacking the transactivation domain, the homeodomain or the octapeptide. Therefore, haplo-insufficiency is the most likely mechanism of dominance of PAX2 mutations in humans. Finally, 12/20 PAX2 gene mutations are either a deletion or an insertion of one or two Gs at position 619 in a stretch of 7 Gs which could be regarded as a mutational hot spot resulting from polymerase slippage. Interestingly, the PAX2 1Neu mutant mouse has been shown to carry the same G insertion at the very same position. Therefore this mouse mutant represents a natural mouse model for PAX2 mutations in humans. 15 In conclusion, our study confirms the critical role of the PAX2 gene in human renal and ocular development, and further demonstrates the wide variation in the clinical spectrum of patients who have PAX2 mutations. PAX2 mutations are responsible for causing renal hypoplasia associated with various ocular manifestations ranging from subtle optic disc anomalies to microphthalmia. In addition, we describe a novel insertion in a mutational polyG hot spot. This type of mutation represent 60% of PAX2 mutations reported so far (12/20) . Finally, the presence of PAX2 germline mosaicism in one family makes genetic counselling difficult in RCS.
